Gene Therapy Clinical Trials for Chronic Granulomatous Disease

本项目涉及进行自体血液干细胞靶向基因治疗慢性肉芽肿病（CGD）的治疗性临床试验。CGD患者有缺陷的循环血液中性粒细胞不能产生杀微生物的过氧化氢。他们反复遭受威胁生命的感染和过早死亡。1997年，我们完成了一项基因治疗慢性肉芽肿病（X-linked form of chronic granulomatous disease, X-CGD）吞噬细胞免疫系统遗传性缺陷的临床试验。在我们的一些基因治疗患者中，高达400分之一的外周血循环中性粒细胞在基因治疗后表现出功能纠正。这种纠正的峰值水平出现在治疗后3至6周，并且在多次输注自体体外基因纠正的CD34+祖细胞治疗的5名患者中，有3名患者的效果可以持续一年以上。这些基因治疗研究表明，通过基因治疗可以对患者的CGD缺陷进行低水平的部分和短暂的纠正。2004年，来自德国的一个治疗X-CGD患者的小组报告了一项类似的CGD基因治疗试验的结果；然而，他们也加入了8mg/kg剂量的化疗药物busulfan，以在骨髓中腾出空间，从而改善移植。他们在外周血中达到了20%的初始水平，然而，基因校正骨髓细胞的生长也导致了水平的增加。然而，这种生长与基因治疗载体通过插入诱变激活MDS1和其他与髓细胞发育相关的基因的克隆的寡克隆性和过度代表性有关。尽管该试验中的患者没有被治愈，而且第一位患者实际上死于败血症，但两位患者似乎都从治疗中获得了一些临床益处，因为他们在移植时都有潜在的感染，在移植前的最初围移植期，这种感染在克隆生长和转导细胞最终沉默之前得到了解决。

This project involves the conduct of therapeutic clinical trials for the treatment of chronic granulomatous disease (CGD) with autologous blood stem cell targeted gene therapy. Patients with CGD have defective circulating blood neutrophils that fail to produce microbicidal hydrogen peroxide. They suffer from recurrent life threatening infections and premature mortality. In 1997, we completed a clinical trial of gene therapy for the inherited deficiency of the phagocytic cell immune system known as the X-linked form of chronic granulomatous disease (X-CGD). In some of our gene therapy treated patients up to 1 in 400 circulating neutrophils in the peripheral blood demonstrated functional correction following the gene therapy. This peak level of correction occurred at 3 to 6 weeks after therapy and the effect could be sustained for over a year in three of five patients treated with multiple infusions of autologous ex vivo gene corrected CD34+ progenitor cells. These gene therapy studies demonstrated that it is possible to provide a low level partial and transient correction of the CGD defect in patients by gene therapy. In 2004, the results of a similar gene therapy trial for CGD was reported by a group from Germany that treated X-CGD patients; however they also included the chemotherapy agent busulfan at a dose of 8mg/kg to make room in the bone marrow and therefore improve engraftment. They achieved initial levels of 20% in the peripheral blood however, there was also an outgrowth of gene corrected myeloid cells resulting in increasing levels. This outgrowth was however associated with oligoclonality and over-representation of clones in which the gene therapy vector had by insertional mutagenesis activated MDS1 and other genes associated with myeloid cell development. Although the patients in this trial were not cured, and the first patient actually expired from sepsis, both patients appeared to have some clinical benefit from the treatment as they each had an underlying infection at the time of their transplant, which resolved in the initial peritransplant period prior to the clonal outgrowth and ultimate silencing of the transduced cells. We therefore initiated a clinical trial in 2006 to treat patients with XCGD and an underlying infection, protocol number 07-I-0017. Based on preclinical data in the rhesus as well as clinical data in a patient, we used busulfan at a dose of 10mg/kg prior to infusion of the genetically modified cells. We treated three patients, the results of which were published in Blood. Of the three patients the first had persistent levels of detectable oxidase positive cells more than 7years post gene therapy; however developed a progressive pulmonary process which despite an attempt at allogeneic transplant, led to his demise in 2016. The second patient treated on this trial appeared to develop an immune reaction against the transduced cells, with rapid clearance of these cells after initially having 5% marking in the peripheral blood. The third patient was treated for a fungal lung infection and had an initial marking level of 4% with a subsequent decline to 0.03% where it remained stable until he underwent a matched unrelated donor transplant due to continued infections. He is now four years out doing well. In 2015 we initiated a collaborative study with two other centres, Protocol 15-I-0008, in order to use a lentiviral vector for X-linked CGD, produced by Genethon. The first patient was treated in Boston in December 2015, and has done relatively well with persistent marking in the 20-25% range. The second patient on the trial was treated at NIH in July 2016, and this patient continues to have marking in the 20-30% range more than 2 years out with no adverse events. The second NIH patient (fourth on the trial) is now over one year post transplant with resolution of his underlying pulmonary fungal infection. Our third patient was treated in early August of 2017 and unfortunately developed autoimmune thrombocytopenia, unrelated to the gene therapy and died of a cerebral hemorrhage. A manuscript describing the results in the first 9 patients including patients treated by investigators in London using the same vector was submitted for publication, but is awaiting review. This does not include our final patient who was treated for an ongoing fungal infection and has had the highest level of marking with more than 70% oxidase cells at his last evaluation. Unfortunately, two patients treated subsequently appear to have had a loss in their marking, although the last patient to be treated appears to be doing well one month out. Thus the protocol is on a voluntary hold until more data is available from the last patient. The vector itself has been licensed to Orchard Therapeutics who hopes to open a registration trial by 2020 to satisfy FDA requirements and obtain eventual approval. We are thus in the midst of designing this new trail in collaboration with the other centers and Orchard Therapeutics. In the interim, we are planning a rescue gene therapy study for those patients at NIH who have an active infection and no matched donor available. The conditioning will be modified given the presence of an active infections. We are also in the midst of developing a multicenter study to treat patients with the autosomal recessive form of CGD affecting the P47 protein using a lentiviral vector and hope to start enrolling patients by late 2019 or early 2020. Future plans will also include incorporating transduction enhancers which have been shown to improve the efficiency of transduction and reduce the amount of vector needed to treat individual patients. We have also continued accrual of plerixafor/GCSF mobilized peripheral blood cells on Protocol 10-I-0016, to assess the impact, if any, of plerixafor on gene transduction of these mobilized cells and had enrolled the last patient to complete the trial, but the patient developed a reaction and we now have to enroll another patient to complete the study. Finally, we have begun working on a lentivector designed for the treatment of patients with CARD9 deficiency in collaboration with Dr Lionakis and his laboratory. Initial testing has resulted in appropriate signaling in a CARD9 deficient cell line when transduced with a vector construct designed by Dr Choi and Caroline Kreitzer.